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Abstract
The objective of the present study was to determine whether lesion of the subthalamic nucleus (STN) promoted by N-methyl-
D-aspartate (NMDA) would rescue nigrostriatal dopaminergic neurons after unilateral 6-hydroxydopamine (6-OHDA) injection 
into the medial forebrain bundle (MFB). Initially, 16 µg 6-OHDA (6-OHDA group) or vehicle (artificial cerebrospinal fluid - aCSF; 
Sham group) was infused into the right MFB of adult male Wistar rats. Fifteen days after surgery, the 6-OHDA and Sham groups 
were randomly subdivided and received ipsilateral injection of either 60 mM NMDA or aCSF in the right STN. Additionally, a 
control group was not submitted to stereotaxic surgery. Five groups of rats were studied: 6-OHDA/NMDA, 6-OHDA/Sham, Sham/
NMDA, Sham/Sham, and control. Fourteen days after injection of 6-OHDA, rats were submitted to the rotational test induced 
by apomorphine (0.1 mg/kg, ip) and to the open-field test. The same tests were performed again 14 days after NMDA-induced 
lesion of the STN. The STN lesion reduced the contralateral turns induced by apomorphine and blocked the progression of 
motor impairment in the open-field test in 6-OHDA-treated rats. However, lesion of the STN did not prevent the reduction of 
striatal concentrations of dopamine and metabolites or the number of nigrostriatal dopaminergic neurons after 6-OHDA lesion. 
Therefore, STN lesion is able to reverse motor deficits after severe 6-OHDA-induced lesion of the nigrostriatal pathway, but 
does not protect or rescue dopaminergic neurons in the substantia nigra pars compacta. 
Key words: Subthalamic nucleus; Parkinson’s disease; Substantia nigra pars compacta; 6-Hydroxydopamine; 
Tyrosine hydroxylase immunohistochemistry 
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Parkinson’s disease (PD) is a progressive neurodegen-
erative disorder that results from a loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc) 
(1). The degeneration of mesencephalic dopaminergic 
cells causes significant dopamine (DA) depletion in the 
corpus striatum, leading to debilitating motor dysfunction 
when DA reduction is greater than 80% (2). PD symptoms 
include akinesia, rigidity, resting tremor, slow movement, 
gait dysfunction, and postural instability (3). 
The striatal DA deficit leads to the disinhibition of the 
indirect pathway of the basal ganglia circuit. As a conse-
quence, the subthalamic nucleus (STN) becomes hyper-
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active in PD (4,5), increasing the excitatory drive of the 
output of basal ganglia nuclei and thereby increasing 
the inhibition of thalamocortical neurons (6). Moreover, 
it has been suggested that STN hyperactivity increases 
the deterioration of existing nigrostriatal dopaminergic 
neurons through excessive glutamatergic stimulation, 
resulting in N-methyl-D-aspartate (NMDA)-mediated 
excitotoxicity and further neuronal loss in PD (3,7,8). 
This is supported by clinical studies showing that altera-
tion in STN activity by high-frequency stimulation (HFS) 
improves motor symptoms in PD (9). 
Thus, it is possible that STN inactivation may have a 
neuroprotective action on the SNpc dopaminergic cells, 
reducing the loss of dopaminergic neurons and decreas-
ing motor impairments in PD (7,10,11). In experimental 
models of PD induced by parkinsonian neurotoxins such 
as 6-hydroxydopamine (6-OHDA) or 1-methyl-2-phenyl-
1,2,3,6-tetrahydropyridine (MPTP), inhibition of STN func-
tion by ablation (12-15), HFS (16,17) or pharmacological 
antagonism (18,19) has been reported to ameliorate some 
of the parkinsonian motor deficits and even to protect 
nigrostriatal dopaminergic neurons against the injury 
induced by these neurotoxins. On the other hand, some 
investigators were unable to find any neuroprotective 
effects of STN inactivation on SNpc neuron survival (20-
22). For this reason, it remains to be determined which 
circuitry is altered in the basal ganglia when glutamater-
gic pathways are suppressed and motor improvements 
take place. It is also important to determine whether the 
increase in striatal DA metabolism is due to an effect on 
the survival of SNpc neurons or if it reflects an altered 
activity of another pathway in the basal ganglia, and also 
if the increase in striatal DA levels is responsible for the 
motor improvement seen in Parkinsonism.
Two protocols are generally used to study gluta-
matergic lesion of the STN. One evaluates the possible 
neuroprotection offered by the lesion and the other, the 
recovery of damaged dopaminergic neurons. In the 
former protocol, the STN lesion is made prior to inject-
ing the neurotoxin, while in the latter the STN lesion is 
performed after injecting it. PD symptoms appear when 
at least 60% of dopaminergic neurons are lost (23). 
Because the rescue protocol is likely to represent more 
closely the clinical condition, the objective of the pres-
ent study was to determine whether STN lesion would 
rescue nigrostriatal dopaminergic neurons after 6-OHDA 
injection into the medial forebrain bundle (MFB). We 
therefore examined the effect of glutamatergic input 
ablation, promoted by NMDA-induced lesion of the STN, 
on the nigrostriatal DA system, as determined by DA and 
metabolite concentrations in the striatum and tyrosine 
hydroxylase (TH)-immunoreactivity in the SNpc. In ad-
dition, in order to confirm the effects of STN ablation on 
parkinsonian motor deficits, behavioral tests of motor 
function were also conducted.
Material and Methods
Animals 
Adult male Wistar rats from our own breeding stock 
weighing 300-400 g at the beginning of the experiments 
were used. The animals were maintained in a temperature-
controlled room (22 ± 2°C) on a 12/12-h light cycle (lights 
on at 7:00 am) and had free access to food and water. All 
studies involving the animals strictly followed the Guide 
for the Care and Use of Experimental Animals (Canadian 
Council on Animal Care) and were approved by the Federal 
University of Paraná Committee of Animal Welfare. Efforts 
were made to minimize animal use and their suffering in 
these experiments. 
Experimental design
Rats received two stereotaxic surgical interventions in 
the right side of the brain. First, 16 µg 6-OHDA (6-OHDA 
group) or vehicle, artificial cerebrospinal fluid (aCSF; Sham 
group), was infused into the right MFB. The control group 
was not submitted to stereotaxic surgery. Fifteen days after 
the first surgery, the 6-OHDA and Sham groups received an 
ipsilateral injection of 60 mM NMDA (6-OHDA/NMDA and 
Sham/NMDA groups) or aCSF in the right STN (6-OHDA/
Sham and Sham/Sham groups). Accordingly, 5 groups 
containing a minimum of 7 rats each, unless otherwise 
stated, were studied: control, Sham/Sham, 6-OHDA/Sham, 
Sham/NMDA, and 6-OHDA/NMDA. Fourteen days after the 
first surgery, rats underwent a behavioral test for locomo-
tor activity, followed 2 h later by the drug-induced rotation 
behavior (first test). The same tests were performed again 
14 days after the second surgery (second test). For neuro-
chemical evaluation, rats were killed by decapitation 2 days 
after the second behavioral test. Brains were removed and 
the striatum tissue was dissected and assayed for DA and 
its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) 
and 4-hydroxy-3-methoxy-phenylacetic acid (HVA). For 
TH immunostaining, rats from the Sham/Sham, Sham/
NMDA, 6-OHDA/Sham, and 6-OHDA/NMDA groups were 
anesthetized and transcardially perfused and the brains 
were removed and processed for immunohistochemistry. 
The absorbance of TH staining and the number of TH-
immunoreactive (TH-ir) neurons were evaluated in the 
SNpc and ventral tegmental area (VTA). In this analysis, 
control groups were not studied since we had previously 
demonstrated that TH-immunoreactivity is similar in control 
and Sham-operated rats (24,25). The number of rats studied 
in each experimental group was 4.
Stereotaxic surgeries
Rats received atropine sulfate (0.4 mg/kg, ip) to sup-
press salivation and penicillin G-procaine (5,000,000 U in 5 
mL, im), and were anesthetized ip with 3 mL/kg equithesin 
(1% thiopental, 4.25% chloral hydrate, 2.13% magnesium 
sulfate, 42.8% propylene glycol, and 3.7% ethanol in water). 
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In the first surgery, 6-OHDA HCl (16 µg in 4 µL aCSF with 
0.2% ascorbate; Sigma, USA) was unilaterally infused (0.5 
µL/min) into the right MFB through a 30-gauge needle. In 
sham-operated rats, 4 µL aCSF was infused into the MFB. 
The coordinates for the injections were: anteroposterior 
(AP), -1.9 mm from bregma, mediolateral (ML), -1.9 mm 
from the midline, dorsoventral (DV), -7.2 mm from the skull, 
as adapted from Paxinos and Watson (26). In the second 
surgery, 1 µL 60 mM NMDA (Sigma) or aCSF was infused 
into the right STN with a 30-gauge needle at 0.5 µL/min. 
The coordinates used were: AP, -3.8 mm from bregma, ML, 
-2.5 mm from midline, DV, -8.1 mm from the skull, adapted 
from Paxinos and Watson (26). To avoid drug reflow, a 2-min 
interval was allowed to elapse between the completion of 
each infusion and withdrawal of the needle. The composi-
tion of aCSF was as follows: 0.15 M NaCl, 2.75 mM KCl, 
1.2 mM CaCl2, and 0.85 mM MgCl2. 
Locomotor activity 
Hypokinesia was evaluated using an open field, which 
consisted of a circular arena (1 m in diameter), with the floor 
divided into 19 sections, limited by a 40-cm circular wall. 
This arena was illuminated by four 60-W lights and placed 
in a sound-attenuated temperature-controlled illuminated 
room. Each rat was placed alone in the center of the arena 
and observed while exploring the open field for 5 min. The 
total number of squares crossed and rearing activity were 
determined over a period of 5 min (27). Before placing an-
other animal, the open field was cleaned with 10% ethanol 
to attenuate odors. All groups were tested for locomotor 
activity 14 days after the first surgery (test 1) and 14 days 
after the second surgery (test 2). 
Drug-induced rotational behavior
Motor asymmetry following unilateral lesion of the ni-
grostriatal pathway was assessed by apomorphine-induced 
rotational behavior. The rats were injected subcutaneously 
with 0.1 mg/kg apomorphine hydrochloride (Sigma) dis-
solved in 0.9% NaCl. Total turns contralateral to the lesion 
were counted over a period of 15 min. All groups were tested 
for rotational behavior 14 days after the first surgery (test 
1) and 14 days after the second surgery (test 2). Repeated 
stimulation with a DA agonist may produce an increase in 
DA-mediated behavioral responses (priming effect). Nev-
ertheless, a two-week interval is probably enough time to 
avoid the priming effect of the first rotational test (12).
Neurochemical assay
Following decapitation, the brains were rapidly removed 
and the striatum tissues were dissected, weighed, imme-
diately frozen on dry ice and stored at -80°C until assayed 
for DA, DOPAC and HVA by high-performance liquid 
chromatography coupled with electrochemical detection 
(HPLC-ED), as previously described (25). The striatum 
tissues were homogenized in 800 µL of a solution contain-
ing 0.2 M perchloric acid (Merck, Germany), 0.1 mM EDTA 
(Merck) and 0.45 µM 3,4-dihydroxybenzylamine (DHBA; 
Aldrich, USA) as the internal standard. The homogenates 
were centrifuged for 20 min at 12,000 g and the supernatant 
was filtered through a 0.22-µm filter (Millex PVDF, Millipore, 
USA). Ten microliters of each sample was injected with an 
auto injector (SIL-10Advp; Shimadzu, Japan) into an HPLC-
ED system. Separation was performed on a 4.6 x 250-mm 
reversed-phase C18 column (Shim-pack VP-ODS, 5 µm; 
Shimadzu), preceded by a 4.6 x 10-mm C18 guard column 
(Shim-pack GVP-ODS, 5 µm; Shimadzu). The mobile phase 
consisted of 100 mM sodium dihydrogen phosphate mono-
hydrate, 10 mM sodium chloride, 0.1 mM EDTA, 0.40 mM 
sodium 1-octanesulfonic acid (Sigma) and 20% methanol 
(Omnisolv, EMD Chemical Inc., USA). pH was adjusted to 
3.5 with phosphoric acid. Flow rate was maintained at 0.9 
mL/min (LC-10Advp; Shimadzu). The detector potential was 
0.65 V vs in situ Ag/AgCl (Decade, VT-03 electrochemical 
flow cell; Antec Leyden, Netherlands). Chromatography 
data were plotted using Class-VP software (Shimadzu). 
DA, DOPAC, and HVA were identified based on their peak 
retention times. Quantification was performed by the internal 
standard method using DHBA as the internal standard based 
on the area under the peak. All samples were measured in 
the same analysis and the intra-assay coefficient of variation 
was less than 5% for all compounds measured. Data were 
normalized by tissue wet weight, and DA and metabolite 
concentrations in the lesioned striatum (right) are reported 
as a percentage of those on the contralateral side. 
Histological evaluation of STN lesion
Cell loss in the STN and the correct location of NMDA 
injection were determined using two-dimensional images 
of Nissl-stained sections (28,29). 
TH immunohistochemistry
Rats were deeply anesthetized with 200 mg/kg sodium 
thiopental, ip, and transcardially perfused with saline fol-
lowed by 4% paraformaldehyde in 0.1 M phosphate buffer 
(PB), pH 7.4 (24,25,28). After perfusion, the brains were 
removed from the skulls, postfixed in the same solution at 
room temperature for 2 h and cryoprotected by immersion 
in 30% sucrose solution in PB at 4°C until they sank. For 
each brain, serial coronal sections (50 µm) were obtained 
with a cryostat (Leitz, Digital 1702, Germany) at -20°C and 
collected in PB. Free-floating sections were pretreated 
with 10% methanol diluted in 3% hydrogen peroxidase for 
30 min, blocked with 3% normal goat serum in 0.1 M PB, 
0.9% NaCl, pH 7.4 (PBS) containing 0.3% Triton X-100 
(PBS-Tx, Sigma) for 30 min and incubated with mouse 
anti-TH antibody (Sigma) at 1:750 in 3% normal goat serum 
in PBS-Tx for 48 h at 4°C. Sections were then incubated 
with a biotinylated secondary antibody (Dako Corporation, 
USA) at 1:200 in PBS-Tx at room temperature for 2 h, and 
with peroxidase-conjugated streptavidin (Dako) at 1:100 
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in PBS for 90 min at room temperature. The antibody-
peroxidase complex was developed by incubating the 
sections in a medium containing 0.06% 3,3 diaminobenzi-
dine (DAB, Sigma) dissolved in PBS for 10 min, and then 
in the same solution containing 1 µM 3% H2O2 per mL of 
DAB medium for 10 min. Next, the sections were rinsed 
with PBS, dehydrated with ethanol, cleared with xylene, 
covered with Permount, and coverslipped. Control sections 
were prepared by omitting the primary antibody and replac-
ing it with PBS. The brains of all animals were fixed and 
postfixed for the same time in the same batch of solution 
rigorously processed at the same time, and the sections 
were incubated in an identical medium for the same period 
of time. This precaution was taken to avoid overreaction, 
differences in chromogen reaction, saturation of absor-
bance, and changes in background levels (24,25,28,30). 
Coronal sections of the SNpc were selected according to 
the atlas of Paxinos and Watson (26) and the readings 
were obtained between the following coordinates: interaural 
4.2 mm, bregma -4.8 mm and interaural -2.7 mm, bregma 
-6.3 mm. In the SNpc and the VTA, the absorbance of the 
TH-ir neurons and the number of TH-ir neurons/mm2 were 
determined as previously described (24,25). Briefly, images 
of coronal sections were digitalized and three equidistant 
areas of interest measuring 1200 µm2 were overlaid onto 
the image to measure absorbance and the number of TH-ir 
neurons/mm2. At least 30 readings in each of 10 sections 
were obtained from each side of the brain. 
Absorbance was calculated using the following for-
mula:
A (x,y) = -log [(intensity(x,y) - black) / (incident - black)]
where: A is absorbance, intensity (x,y) is the intensity at 
pixel (x,y), black is the intensity generated when no light 
goes through the material (5.3 in our case), and incident 
is the intensity of the incident light (252.4 in our case). 
To determine neuronal density, the sum of TH-ir neurons 
located inside this square or intersected by the lower and/
or right edge of the square were counted. The neurons 
that were intersected by the upper and/or left edge of the 
square were not counted (24,25,28).
Count and absorbance measurements were carried 
out by two specialists in histology blind to the source of the 
images. All procedures were done using a Nikon Eclipse 
E-600 (50X) microscope coupled to a Pro-Series High 
Performance CCD camera and Image Pro Plus Software 
4.1 (Media Cybernetics, USA). 
Statistical analysis
Data are reported as means ± SEM. Behavioral and 
neurochemical data were analyzed by one-way analysis 
of variance (ANOVA) and TH immunohistochemical data 
by two-way and one-way ANOVA. In all analyses, ANOVA 
was followed by the Duncan post hoc test. Differences be-
tween the first and second behavioral tests were analyzed 
by the Student t-test for dependent samples. P < 0.05 was 
considered to be statistically significant.
Results
Drug-induced rotational behavior
Contralateral turns induced by apomorphine were in-
creased in the 6-OHDA groups in the first test compared 
to Sham and control groups (F4,38 = 12.29, P < 0.01), 
as shown in Figure 1. In the second test, the number of 
contralateral turns observed in the 6-OHDA/Sham group 
was greater than all the other groups (F4,38 = 10.57, P < 
0.01). When each group was analyzed considering the first 
vs the second test, the 6-OHDA/NMDA group showed a 
significant reduction in total contralateral turns (t = 3.37, 
P < 0.01). On the other hand, the number of contralateral 
turns increased in the 6-OHDA/Sham group (t = 2.37, P < 
0.05). There were no significant differences between the 
first and second tests of the control, Sham/Sham or Sham/
NMDA groups.
Locomotor activity
Analysis of the total squares crossed in the open field 
Figure 1. Total number of apomorphine-induced contralateral 
turns during a period of 15 min. Data are reported as means ± 
SEM for the following groups: control (N = 8), SNpc sham le-
sion/STN sham lesion (Sham/Sham; N = 7), SNpc sham lesion/
STN NMDA lesion (Sham/NMDA; N = 8), SNpc 6-OHDA lesion/
STN sham lesion (6-OHDA/Sham; N = 10), and SNpc 6-OHDA 
lesion/STN NMDA lesion (6-OHDA/NMDA; N = 10) in the first 
and second tests. SNpc = substantia nigra pars compacta; STN 
= subthalamic nucleus; NMDA = N-methyl-D-aspartate; 6-OHDA 
= 6-hydroxydopamine. *P < 0.01 compared to the other groups 
in the first test; #P < 0.01 compared to the other groups in the 
second test (one-way ANOVA). +P < 0.05 compared to the first 
test in the same group. ++P < 0.01 compared to the first test in the 
same group (Student t-test). 
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(Figure 2A) showed that, in the first test, 6-OHDA animals 
exhibited reduced exploratory activity compared to control 
and Sham animals (F4,47 = 5.19, P < 0.01). In the sec-
ond test, the 6-OHDA groups still crossed fewer squares 
compared to the control and Sham groups (F4,47 = 17.17, 
P < 0.001); however, the reduction was attenuated in the 
6-OHDA/NMDA group when compared to the 6-OHDA/
Sham group (P < 0.05). In the 6-OHDA/Sham group, there 
was a greater decrease in the number of squares crossed in 
the second test compared to the first (t = 5.92, P < 0.001). 
This further reduction was prevented by the STN lesion in 
the 6-OHDA/NMDA group (t = 0.45, P = 0.66). There were 
no significant changes between the first and second tests 
in control, Sham/Sham and Sham/NMDA groups.
As illustrated in Figure 2B, evaluation of rearing move-
ments in the open field showed results similar to those 
for the squares crossed. In the first test, 6-OHDA groups 
exhibited fewer rearing movements than control and Sham 
groups (F4,47 = 11.12, P < 0.001). In the second test, the 
6-OHDA groups still exhibited decreased rearing activity 
compared to control and Sham groups (F4,47 = 11.99, P < 
0.001). However, the reduction was smaller in the 6-OHDA/
NMDA group than in the 6-OHDA/Sham group (P < 0.05). 
In the 6-OHDA/Sham group, rearing activity was further 
reduced in the second test compared to the first one (t = 
4.89, P < 0.001). This further reduction was prevented by 
the STN lesion in the 6-OHDA/NMDA group (t = 0.26, P = 
0.80). There were no significant changes between the first 
and second tests in the control, Sham/Sham and Sham/
NMDA groups.
Histological evaluation of STN lesion
The number of neurons in the STN was quantified in 
the right and the left hemisphere. NMDA injection promoted 
a significant lesion in the STN with a cell loss of approxi-
mately 84% in the right versus the left hemisphere, without 
involvement of adjacent nuclei (Figure 3). 
Neurochemical assay
Analysis of DA, DOPAC, and HVA concentrations in the 
non-lesioned striatum (left side) revealed no significant dif-
ferences between the control, Sham/Sham, Sham/NMDA, 
6-OHDA/Sham, and 6-OHDA/NMDA groups. In the left 
striatum, the average DA, DOPAC, and HVA concentrations 
were 5.89 ± 0.62, 3.37 ± 0.16 and 0.67 ± 0.03 ng/mg tissue 
(mean ± SEM), respectively. These data validated the use 
of contralateral values as controls for the unilateral lesion of 
the nigrostriatal pathway. There was a significant decrease 
in striatal DA (F4,28 = 32.04, P < 0.001), DOPAC (F4,28 = 
43.00, P < 0.001) and HVA (F4,28 = 66.54, P < 0.001) con-
centrations in the groups treated with 6-OHDA compared 
to the other groups (Figure 4). On the other hand, the STN 
lesion in Sham and 6-OHDA-lesioned rats did not alter the 
striatal concentrations of DA (P = 0.99), DOPAC (P = 0.99) 
or HVA (P = 0.99) compared to Sham/Sham and 6-OHDA/
Sham rats, respectively.
Figure 2. Open-field locomotor activity during a 5-min period. Data are reported as means ± SEM for the following groups: control 
(N = 10), SNpc sham lesion/STN sham lesion (Sham/Sham; N = 10), SNpc sham lesion/STN NMDA lesion (Sham/NMDA; N = 10), 
SNpc 6-OHDA lesion/STN sham lesion (6-OHDA/Sham; N = 11), and SNpc 6-OHDA lesion/STN NMDA lesion (6-OHDA/NMDA; N = 
11) in the first and second tests. SNpc = substantia nigra pars compacta; STN = subthalamic nucleus; NMDA = N-methyl-D-aspartate; 
6-OHDA = 6-hydroxydopamine. A, Total squares crossed. *P < 0.01 compared to the other groups in the first test; #P < 0.001 compared 
to the other groups in the second test; ♦P < 0.05 compared to the 6-OHDA/NMDA group in the second test (one-way ANOVA). +P < 
0.001 compared to the first test in the same group (Student t-test). B, Total number of rearing movements. *P < 0.001 compared to the 
other groups in the first test; #P < 0.001 compared to the other groups in the second test; ♦P < 0.05 compared to the 6-OHDA/NMDA 
group in the second test (one-way ANOVA). +P < 0.001 compared to the first test in the same group (Student t-test). 
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TH immunohistochemistry
Injection of 6-OHDA into the MFB significantly decreased 
the absorbance of TH immunostaining (F1,28 = 92.34, P < 
0.001) and the number of TH-ir neurons (F1,28 = 32.71, 
P < 0.001) in the SNpc, as illustrated in Figures 5 and 
6A and B. STN lesion did not protect the SNpc neurons 
from 6-OHDA-induced lesion, as determined by the equal 
decrease in absorbance (P = 1.00) or neuronal density 
(P = 0.74) of TH-ir neurons. In the VTA, there was also a 
6-OHDA-induced decrease in the absorbance of TH (F1,28 
= 29.99, P < 0.001) and number of TH-ir neurons (F1,28 = 
29.61, P < 0.001; Figures 5 and 6C and D). As also observed 
for the SNpc, TH immunostaining did not differ between the 
6-OHDA/NMDA and 6-OHDA/Sham groups. 
STN lesion and behavioral effects
The effect of STN lesion in rats recovering from anes-
thesia following aCSF (Sham/NMDA group) or 6-OHDA (6-
OHDA/NMDA) infusion into the MFB was the manifestation 
of a marked contralateral hemiballismus. This response was 
transient, lasting approximately 16 h. Temporary hemibal-
lismus has also been described in rats awakening from 
Figure 3. Digitized images of coronal 
sections of the subthalamic nucleus in 
the right (R) and left (L) hemispheres. 
Note a severe loss of neurons in the left 
STN after unilateral NMDA injection. The 
schematic drawings were modified from 
the Paxinos and Watson atlas (26). IC = 
internal capsule; OPT = optic tract; STN = 
subthalamic nucleus.
200 µm
100 µm
500 µm
1 mm
STN
IC OPT
Figure 4. Neurochemical analysis of DA, DOPAC and HVA concentrations in the striatum. Percentage of DA, DOPAC and HVA levels 
remaining on the lesioned side (right) compared with the non-lesioned side of the following groups: control (N = 6), SNpc sham lesion/
STN sham lesion (Sham/Sham; N = 6), SNpc sham lesion/STN NMDA lesion (Sham/NMDA; N = 7), SNpc 6-OHDA lesion/STN sham 
lesion (6-OHDA/Sham; N = 7), and SNpc 6-OHDA lesion/STN NMDA lesion (6-OHDA/NMDA; N = 7). Data are reported as means ± 
SEM. DA = dopamine; DOPAC = 3,4-dihydroxyphenylacetic acid; HVA = 4-hydroxy-3-methoxy-phenylacetic acid; SNpc = substantia 
nigra pars compacta; STN = subthalamic nucleus; NMDA = N-methyl-D-aspartate; 6-OHDA = 6-hydroxydopamine. *P < 0.001 com-
pared to control, Sham/Sham and Sham/NMDA groups (one-way ANOVA)
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Figure 5. Digitized images of TH immunohistochemistry in the SNpc and VTA after different treatments. Note decreased TH-immunore-
activity in the right SNpc and VTA in response to 6-OHDA injection into the right medial forebrain bundle. Photomicrographs represent 
TH immunostaining in the following groups: SNpc sham lesion/STN sham lesion (Sham/Sham), SNpc sham lesion/STN NMDA lesion 
(Sham/NMDA), SNpc 6-OHDA lesion/STN sham lesion (6-OHDA/Sham), and SNpc 6-OHDA lesion/STN NMDA lesion (6-OHDA/
NMDA). SNpc = substantia nigra pars compacta; SNpr = substantia nigra pars reticulata; STN = subthalamic nucleus; NMDA = N-
methyl-D-aspartate; 6-OHDA = 6-hydroxydopamine; VTA = ventral tegmental area.
(16 µg 6-OHDA)
3 mm
SNpc
SNpr
VTA
1 mm
1 mm
Bregma: -5.30 mm
Interaural: 3.70 mm
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anesthesia following NMDA lesion of the STN (14).
Discussion
The mechanism responsible for the improvement of 
motor symptoms in PD after reversible or definitive inhibi-
tion of the STN is still unknown. In the present study, we 
determined whether STN lesion-induced motor recovery 
could be explained by the rescue of nigrostriatal dop-
aminergic neurons in a 6-OHDA-lesion rat model of PD. 
Our results show that STN lesion performed 15 days after 
6-OHDA lesion of the nigrostriatal pathway reduced the 
apomorphine-induced rotational behavior. These data agree 
with previous reports that STN lesion reduces the number 
of apomorphine-induced contralateral rotations (4,12,15). 
However, we found no improvement of hypokinesia in the 
open-field test. STN lesion has been shown to improve 
some, but not all, parkinsonian signs (14). Despite the lack 
of total recovery of motor function, STN lesion blocked 
the progression of motor impairment from the first to the 
second behavioral test in 6-OHDA-treated animals. Our 
experimental design was therefore effective in reproducing 
the anti-parkinsonian effects of STN lesion. 
Our study did not detect an effect of STN lesion on the 
number of surviving TH-ir cells in the SNpc or VTA after 
6-OHDA lesion of the MFB. Our results show a decrease of 
about 50% in the number of TH-ir neurons per mm2 in the 
SNpc of animals treated with 6-OHDA and an apparently 
greater decrease in the absorbance measurements related 
to TH in the same groups. This apparent discrepancy can 
be explained by the fact that there is no linear correlation 
between neuronal density and absorbance measurements, 
because, regarding absorbance, the light absorbed by the 
tissue conforms to the Lambert-Beers law and is presented 
on a logarithmic scale, while the neuronal density is pre-
sented on an arithmetic scale (26,30). 
Our results showing that STN lesion did not affect the 
number of surviving TH-ir cells in the SNpc or VTA after 
6-OHDA agree with the results of Bilbao et al. (20) who 
reported that subthalamotomy after 6-OHDA lesion did 
not promote immunohistochemical or electrophysiological 
changes in the nigrostriatal system. Luquin et al. (22) con-
ducted a study on two groups of non-human primates, one 
subjected to STN lesion before MPTP administration and 
the other subjected to lesion after MPTP administration. In 
the second case, STN lesion produced an improvement of 
Figure 6. TH immunohistochemistry in the SNpc and VTA. A and C, Tyrosine hydroxylase-immunoreactive (TH-ir) neuron density (neu-
rons/mm2). B and D, TH immunostaining absorbance. Data are reported as means ± SEM on the right and left sides for the following 
groups: SNpc sham lesion/STN sham lesion (Sham/Sham; N = 4), SNpc sham lesion/STN NMDA lesion (Sham/NMDA; N = 4), SNpc 
6-OHDA lesion/STN sham lesion (6-OHDA/Sham; N = 4), and SNpc 6-OHDA lesion/STN NMDA lesion (6-OHDA/NMDA; N = 4). SNpc 
= substantia nigra pars compacta; STN = subthalamic nucleus; NMDA = N-methyl-D-aspartate; 6-OHDA = 6-hydroxydopamine; VTA = 
ventral tegmental area. *P < 0.001 compared to the Sham/Sham and Sham/NMDA groups (Duncan test after two-way ANOVA). 
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movements, but nigral degeneration was neither reduced nor 
prevented by prior STN lesion. A similar result was also obtained 
for monkeys undergoing subthalamotomy before MPTP.
An elegant study by Paul et al. (5) investigated the po-
tential neuroprotective effects of STN lesion on SNpc cells 
lesioned with 6-OHDA two weeks later. Using fluorogold 
and TH-immunoreactivity as markers of cell survival and 
dopaminergic phenotype, respectively, they showed that 
ablation of the STN led to a partial recovery of amphetamine-
induced rotational behavior, but did not affect the number of 
fluorogold-ir cells, whereas it increased the number of TH-ir 
cells. This suggests that STN lesion may have rescued the 
neurotransmitter phenotype in the remaining cells. In our 
study, if a recovery of impaired SNpc cells had occurred, 
increased striatal DA levels would be expected. Neverthe-
less, whereas 6-OHDA caused a decrease greater than 
95% in striatal DA, DOPAC and HVA concentrations, the 
STN lesion had no effect on the concentrations of striatal 
DA and its metabolites. This means that, at least under the 
experimental conditions of the present study, the STN lesion 
neither preserved SNpc cells from death nor recruited the 
DA phenotype. Some studies using deep brain stimulation 
(17,31) have shown enhanced DA or metabolite levels in 
the striatum, suggesting a mechanism whereby STN HFS 
improves motor symptoms in PD. However, the improvement 
of motor symptoms observed here cannot be explained by 
the increased release of DA in the striatum from residual 
dopaminergic neurons. Thus, it seems that the mechanism 
of action involved in the improvement of motor symptoms 
by STN lesion requires additional study. It is unlikely that 
the absence of dopaminergic protection was due to an 
incomplete lesion of the STN, because NMDA lesion was 
able to reverse the motor deficits induced by 6-OHDA and 
to promote transitory contralateral hemiballism. 
Bilbao et al. (20), studying the electrophysiology of SNpc 
neurons and the effects of subthalamotomy and levodopa 
treatment before 6-OHDA lesion, showed that 4 µg 6-OHDA 
caused a neuronal loss of almost 50% and that subthalamo-
tomy did not modify the neuronal firing pattern or the reduction 
in TH-ir neurons. The 6-OHDA dose used in the present study 
(16 µg) promoted an extensive loss of dopaminergic cells, 
approximately 57%. This suggests that, in case of severe 
injury, when more than 50% of cells are lost, the STN lesion 
may not exert neuroprotection. Accordingly, Luquin et al. (22) 
showed that STN lesion did not protect the SNpc neurons 
against MPTP toxicity, promoting a TH-ir cell death rate of 
over 80%. In addition, Fang et al. (16) reported that in mild 
PD models, with less than 50% of neuronal loss, the inhibitory 
state is easily corrected by STN HFS, whereas in severe PD 
models (more than 70% of neuronal loss) the parkinsonian 
symptoms are more resistant to treatment.
Some investigators have reported that STN lesion pre-
vented the loss of dopaminergic neurons in the SNpc after 
intrastriatal injection of 6-OHDA in rats (13,32). However, 
the protection obtained following STN lesion was more 
effective when the lesion was performed before 6-OHDA 
administration rather than after it. Interestingly, it has been 
recently shown that intrapallidal injections of glutamate 
receptor agonists also promote suppressive effect on ro-
tational behavior of 6-OHDA-lesioned rats, without altering 
dopaminergic degeneration (33). 
Our data showed that motor deficits display an important 
improvement after STN lesion, indicating the existence of a 
more complex physiological network within the basal ganglia 
or the existence of other excitatory pathways that could be 
influenced by STN inactivation. Although numerous studies 
have suggested that the excitatory response observed in 
SNpc neurons is due to direct glutamatergic afferents from 
the STN (34), the pedunculopontine nucleus is the major 
source of glutamatergic input to SNpc neurons (35). Ac-
cordingly, Takada et al. (36) reported that pedunculopontine 
nucleus lesion attenuated the cell loss and parkinsonian 
motor deficits in MPTP-treated monkeys. 
The glutamatergic projections from the STN alter the 
physiology of the globus pallidus (GPi), and changes in the 
neuronal activity of GPi have been shown in animal models 
of PD. Ni et al. (37), using electrophysiological recordings 
of GPi cells in rats with 6-OHDA lesion, concluded that the 
STN plays an important role in the modulation of GPi neuron 
activity, which might account for the therapeutic effect of 
STN lesion in PD. 
Finally, another glutamatergic pathway to be considered 
is the STN projection to the striatum. A direct projection 
from the STN to the striatum, though less abundant (34), 
could account for a decreased glutamatergic activity in the 
striatum after STN lesion (4,38). Supporting this idea, it has 
been reported that the beneficial effects of STN inactivation 
on parkinsonian symptoms are correlated with alteration in 
glutamatergic transmission in the striatum (4,15,39), which 
is similar to the beneficial effects promoted by levodopa 
treatment. Moreover, STN lesion may also affect the activity 
of thalamo-cortical projections and thereby alter glutamate 
levels in the striatum. Accordingly, Luquin and Mitrofanis 
(40) have shown that previous removal of cortical inputs 
was able to protect SNpc cells against 6-OHDA lesion. Thus, 
the STN lesion-induced improvement in motor alterations 
might not be due to a direct effect of the lesion, but to an 
indirect effect on cortical/striatal activity. 
Using the rescue protocol, which has clinical relevance, 
our data show that STN lesion is able to reverse motor defi-
cits after severe 6-OHDA-induced lesion of the nigrostriatal 
pathway without rescuing dopaminergic neurons in the SNpc. 
Further studies are necessary to clarify the STN pathways 
involved in the improvement of motor symptoms in PD. 
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